Rislenemdaz

CAS No. 808732-98-1

Rislenemdaz( MK-0657 | CERC-301 | MK 0657 | MK0657 | CERC 301 | CERC301 )

Catalog No. M16023 CAS No. 808732-98-1

A potent, orally bioavailable brain‐penetrant, NR2B-selective NMDA receptor (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 197 In Stock
5MG 179 In Stock
10MG 283 In Stock
25MG 472 In Stock
50MG 642 In Stock
100MG 865 In Stock
200MG 1163 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Rislenemdaz
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, orally bioavailable brain‐penetrant, NR2B-selective NMDA receptor (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM respectively.
  • Description
    A potent, orally bioavailable brain‐penetrant, NR2B-selective NMDA receptor (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM respectively, with no off-target activity; inhibits calcium influx into agonist‐stimulated NMDA‐GluN1a/GluN2B L(tk‐) cells with IC50 of 3.6 nM, with no effect on GluN2A up to 30 uM; significantly decreases immobility frequency and increases swimming behavior in acute depression models.Depression Phase 1 Clinical.
  • In Vitro
    Rislenemdaz (CERC-301) inhibits calcium influx into agonist-stimulating NMDA-GluN1a/GluN2B L(tk-) cells with an IC50 of 3.6 nM. Rislenemdaz exhibits at least 1000× selectivity for the GluN2B receptor versus all targets tested, including the hERG potassium channel. Rislenemdaz also exhibits minimal activity against sigma-type receptors at 10 uM.
  • In Vivo
    Rislenemdaz (CERC-301) (1, 3, 10, and 30 mg/kg) significantly decreases immobility frequency (P<0.001) and significantly increases swimming behavior (P<0.01 for 1, 3, and 30 mg/kg; P<0.05 for 10 mg/kg) compare to the vehicle control.Rislenemdaz plasma levels are approximately 15, 120, 390, 1420, 4700, and 14,110 nM (0.015, 0.120, 0.390, 1.42, 4.7, and 14.11 uM) at the time of sampling, corresponding to approximately 5, 29, 56, 83, 94, and 98% RO, respectively, in rats. The ED50 for increaing in frequency of swimming and decreasing in immobility are ~0.3 and 0.7 mg/kg, respectively, corresponding to RO of ~30 and 50%. Rislenemdaz (1, 3, 10, and 30 mg/kg) significantly increases total distance traveling (P<0.01 for 1 mg/kg; P<0.001 for 3, 10, and 30 mg/kg) compare to vehicle control over the 60 min test.
  • Synonyms
    MK-0657 | CERC-301 | MK 0657 | MK0657 | CERC 301 | CERC301
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    iGluR
  • Recptor
    iGluR
  • Research Area
    Neurological Disease
  • Indication
    Depression

Chemical Information

  • CAS Number
    808732-98-1
  • Formula Weight
    358.417
  • Molecular Formula
    C19H23FN4O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 150 mg/mL 418.52 mM
  • SMILES
    CC1=CC=C(C=C1)COC(=O)N2CCC(C(C2)F)CNC3=NC=CC=N3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Addy C, et al. J Clin Pharmacol. 2009 Jul;49(7):856-64. 2. Ibrahim L, et al. J Clin Psychopharmacol. 2012 Aug;32(4):551-7. 3. Garner R, et al. Pharmacol Res Perspect. 2015 Dec 23;3(6):e00198.
molnova catalog
related products
  • Eliprodil

    Eliprodil (SL-820715) is a non-competitive NR2B-NMDA receptor antagonist, less potent for NR2A- and NR2C-containing receptors (IC50>100 uM).

  • TAK-137

    TAK-137 is an AMPA receptor enhancer with antidepressant effects. TAK-137 has the ability to improve cognition and could be used to study schizophrenia.

  • NS-1209

    A selective, water-soluble, in vivo long-lasting AMPA antagonist with Ki of 43 nM; display selectivity for the [3H] AMPA over the [3H]kainate- (IC50=81 uM), [3H]CGS19755, and [3H]glycine-binding sites (IC50 > 30 uM) in rat cortical membranes.